Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

Share Price is delayed by 15 minutes
Get Live Data
5.75    -0.10 (-1.71%)
Bid:
5.70
Ask:
5.80
Spread: 0.10 (1.754%)
Market Cap: £61.50m
STX Live PriceLast checked at - London Stock Exchange

Intraday Shield Thera Share Chart

Holding(s) in Company

12 Jan 2023 14:40

RNS Number : 5809M
Shield Therapeutics PLC
12 January 2023
 

 

 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are at- tached ii:

 

Shield Therapeutics plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

x

Other (please specify) iii:

3. Details of person subject to the notification obligation iv

Name

W. Health L.P. ("Inventages")

City and country of registered office (if applicable)

The Bahamas

4. Full name of shareholder(s) (if different from 3.) v

Name

CGWL Nominees Limited

City and country of registered office (if applicable)

London, UK

5. Date on which the threshold was crossed or reached vi:

 

6 January 2023

6. Date on which issuer notified (DD/MM/YYYY):

11 January 2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights at- tached to shares (to- tal of 8. A)

% of voting rights through financial instru- ments

(total of 8.B 1 + 8.B 2)

 

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A +

8.B) vii

Resulting situation on the date on which threshold was

crossed or reached

 

9.56%

 

0%

 

9.56%

 

56,008,541

Position of previous notification (if applicable)

 

21.76%

 

0%

 

21.76%

 

 

 

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type of shares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00BYV81293

56,008,541

0

9.56%

0%

SUBTOTAL 8. A

56,008,541

9.56%

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

 

Type of financial in- strument

 

Expiration date x

 

Exercise/ Conversion Period xi

Number of voting rights that may be acquired if the instrument is exercised/converted.

 

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expiration date x

Exercise/ Conversion Pe- riod xi

Physical or cash Settlement xii

Number of voting rights

 

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

 

 

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

x

Full chain of controlled undertakings through which the voting rights and/or the

financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

 

 

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial in- struments if it equals or is higher than the

notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

 

 

 

Place of completion

The Bahamas

Date of completion

11 January 2023

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLBTMITMTTBBJJ
Date   Source Headline
29th May 20269:11 amRNSTotal Voting Rights
5th May 20267:00 amRNSGrant of Share Options
1st May 20267:00 amRNSQ1 2026 Trading Update
30th Apr 20267:01 amRNSTotal Voting Rights
27th Apr 20267:00 amRNSEnrollment in Phase II Clinical Trial for ACCRUFeR
9th Apr 202612:30 pmRNSAudited results for year ended 31 December 2025
1st Apr 20269:22 amRNS-RPublication of Report, Reinforcing FDA Approval
31st Mar 20267:03 amRNSTotal Voting Rights
31st Mar 20267:00 amRNSEMA approves extension - to include adolescents
3rd Mar 20267:00 amRNSChinese NMPA Accepts MAA Submission for ACCRUFeR®
27th Feb 20267:00 amRNSTotal Voting Rights
9th Feb 20267:00 amRNSFDA Grants additional Exclusivity for ACCRUFeR
30th Jan 20267:05 amRNSTotal Voting Rights
30th Jan 20267:00 amRNSApproval for ACCRUFeR in China expected in Q1 2026
21st Jan 20267:00 amRNSQ4 2025 Trading Update
2nd Jan 202611:06 amRNSBlock listing 6 Monthly Return
2nd Jan 20267:00 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSTotal Voting Rights
22nd Dec 20257:00 amRNSFDA approves extension for ACCRUFeR®
22nd Dec 20257:00 amRNSFDA approves extension for ACCRUFeR®
18th Dec 20257:13 amRNSBlock Listing Application
11th Dec 20257:00 amRNS-RShield Wins Gold at Titan Branding Awards
3rd Dec 20257:04 amRNSAmends Senior Secured Debt Financing
14th Nov 20257:03 amRNSInitiation of a Phase II Clinical Trial in Japan
11th Nov 20257:00 amRNSACCRUFeR Pediatric PK Results to be Presented
7th Nov 20257:03 amRNSACCRUFeR receives Authorisation by Korean Ministry
23rd Oct 20257:00 amRNSQ3 2025 Trading Update
14th Oct 20253:01 pmRNSGrant of Share Options to Chief Executive Officer
1st Oct 20258:00 amRNSTotal Voting Rights
1st Oct 20257:02 amRNSPositive efficacy and tolerance in pediatric trial
15th Sep 20257:00 amRNS£1.5 million placing supporting growth of ACCRUFeR
4th Sep 20257:03 amRNSACCRUFeR® assigned Priority Review in US by FDA
3rd Sep 20252:17 pmRNSInterim results for the six months ended 30 Jun 25
27th Aug 20257:13 amRNSData published -European Journal of Heart Failure
21st Aug 202512:06 pmRNSInterim results for the six months ended 30 Jun 25
23rd Jul 20257:00 amRNSQ2 2025 Trading Update
22nd May 20255:06 pmRNSResult of AGM
24th Apr 20257:06 amRNSAudited results for the year ended 31 Dec 2024
22nd Apr 20257:01 amRNSLicence Agreement in Japan for ACCRUFeR®
17th Apr 202511:23 amRNSQ1 2025 Trading Update
11th Mar 20257:00 amRNSACCRUFeR® launched in Canada
13th Feb 20254:15 pmRNSPDMR Transaction Notification
13th Feb 20257:00 amRNSGrant of Share Options
5th Feb 20257:00 amRNSUnaudited full year trading update
27th Jan 20257:00 amRNSAnders Lundstrom appointed CEO
24th Dec 202411:25 amRNSResult of General Meeting & Total Voting Rights
23rd Dec 20247:00 amRNSResults of RetailBook Offer
6th Dec 202411:31 amRNSRetailBook Offer
6th Dec 202411:30 amRNSSubscription by AOP Health to raise US$10 million
21st Nov 20247:00 amRNSBusiness Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.